We make the intro.
You close the deal.
Find your target investor in ZenithOS. Request a warm intro. Lavine reaches out through her life sciences network — and only connects you if the investor opts in first.
Investor network includes
3,262
Life sciences investors
24h
Average first response
72h
Typical opt-in turnaround
100%
Life sciences focus
Platform
Three things ZenithOS does.
Find the right fund. Know they're actively deploying. Get the intro — double opt-in, no cold reach.
Investor Search
Browse 3,262 life sciences investors filtered by stage, therapeutic area, check size, and lead/follow preference.
- Stage filter — Seed through Series C
- Therapeutic area & disease focus
- Check size & co-investment history
- Non-dilutive sources included
Active Mandate Tracking
Know who's deploying before you reach out. See last deal activity, fund status, and named partner thesis.
- Last deal activity date
- Current fund deployment status
- Named partner focus areas
- Verified contact details
Warm Intro Pathway
Request a warm intro through Lavine's network. She pitches the investor first — no surprise intros.
- 24h fit review by Lavine
- Double opt-in before you're named
- Proper email intro with context
- Honest feedback if fit isn't there
Not sure where to start?
Describe your raise and we'll match you to the right investors in plain English.
Sound familiar?
Common Frustrations, Solved.
Life sciences fundraising is broken in specific, predictable ways. ZenithOS is built to fix them.
Investor depth
Built for every area of life sciences.
If you can name the therapeutic area, we have investors that focus on it — with verified active mandates.
Numbers reflect active investors across 3,262 tracked profiles · Updated quarterly
The process
What happens after you click the button
You find the investor
You · 2 minBrowse 3,262 investors or describe your raise in plain language. Find the exact partner that fits your stage, area, and check size.
You request the intro
You · 1 minClick "Request warm intro via Zenith." An email opens to Lavine with the investor, your details, and a place to attach your deck.
Lavine reviews fit
Zenith · 24hLavine reviews your company against the investor's actual thesis. She checks her direct relationships for the strongest path — or tells you honestly if the fit isn't there.
Double opt-in
Zenith + Investor · 24–72hLavine contacts the investor first — before your name is mentioned. She pitches the opportunity and confirms they're open. No surprise intros.
The intro lands
Zenith · After opt-inA proper email intro with context — why this company, why this fund, why now. Both parties CC'd. You take it from there.
The intro email
What it actually looks like
Kevin,
Wanted to connect you with Sarah Chen, founder of Radiant Bio — a Series A oncology platform company developing next-generation CAR-T therapies for solid tumors. They're closing a $15M round.
Sarah's team includes former Novartis and Blueprint Medicines scientists. I reviewed the deck — the differentiation is real and I think this fits squarely in Third Rock's wheelhouse.
Sarah is absolutely open to a conversation. Over to you both.
Lavine
Zenith — zenith-grp.co
Illustrative example. Names and companies are fictional.
Founders
Trusted By Founders
Life sciences companies that used ZenithOS to find, reach, and close their investors.
Sarah Chen
CEO & Co-Founder · Radiant Bio
"Lavine had the right intro lined up within 48 hours. The investor had already been briefed on us before the call — that never happens with a cold reach-out."
Marcus Osei
Founder & CEO · NovaStem Therapeutics
"The database alone saved us weeks of research. Finding the right Seed-stage gene therapy fund used to take a consultant and three months. We did it in an afternoon."
Priya Rajan
Co-Founder & CSO · Helix Diagnostics
"The double opt-in process is what makes this real. The investor knew what they were walking into. First call was a genuine conversation, not a pitch-and-pray."
Tom Lund
CEO · Carta Immunology
"We'd been trying to get in front of one fund for six months. Lavine got us a call in a week. Deal closed two months later."
Ananya Kumar
Founder · Lumio Therapeutics
"What sets ZenithOS apart isn't just the database — it's that someone actually knows these investors personally and can vouch for you before you walk in."
James Hartley
CEO & Co-Founder · PrecisionNeuro
"I'd tried every platform. ZenithOS was the first one where we actually got responses — because the intro came with credibility attached."
$66M+
Raised by founders in network
6
Active portfolio companies
100%
Life sciences focus
Who makes the intro
Lavine Hemlani
LinkedInFounder, Zenith · Life Sciences Financial Advisory · lavine@zenith-grp.co
Lavine is a life sciences financial advisor who has spent years building relationships across the biotech and medtech investment ecosystem — from early Seed funds to late-stage crossover investors. She founded Zenith to give founders direct access to the investor network that used to take a decade to build.
Before making an intro, she reads your deck, checks current thesis alignment, and pre-pitches the opportunity. If the fit isn't real, she tells you — and points you somewhere better.
How we work together
Simple, transparent services.
Start with a free intro request. Expand as your raise gets serious.
Intro Access
Free
No commitment required
For founders who need the right door opened.
- Full access to 3,262 investor profiles
- Filter by stage, area & check size
- Unlimited warm intro requests
- 24h response from Lavine
- Double opt-in — no surprise intros
CFO Advisory
Custom
Monthly retainer
Fractional CFO support through your raise and beyond.
- Everything in Intro Access
- Financial modeling & projections
- Investor memo & data room build-out
- Term sheet review & negotiation
- Board reporting & KPI tracking
- Monthly strategic finance sessions
Fundraise Mandate
Custom
Success-based structure
End-to-end fundraising from first pitch to close.
- Everything in CFO Advisory
- Investor targeting & outreach strategy
- Full pitch process management
- Negotiation & close support
- Post-close cap table & reporting
Questions
Common questions
Ready to request an intro?
Browse 3,262 life sciences investors. Find your target. Request the intro. Lavine handles the rest.